The HLA/Immunogenetics Laboratory, directed by Dr. Elizabeth Trachtcnbcrg at Children'sHospital & Research Center at Oakland (CHRCO), will take the role as KIR Genotyping Core Laboratory to examine the heterogeneity of KIR and role of K1R-HLA associations in unrelated blood and marrow transplantation outcome. The CHRCO HLA/Immunogenetics Laboratoryis a California State licensed clinical histocompatibility and immunogenetics laboratory with CLIA, JCHAO, ASHI and C'APaccreditation. The CHRCO HLA/Immunogenetics Laboratory director and personnel are experienced with high-throughput, high complexity genetic analyses and assay development, and have the necessary quality control and quality assurance expertise to fulfill this role. In the first year, the Laboratory will begin the KIR genotyping using established molecular methods, including PCR and sequence-specific oligonucleotidc (SSO) probeprotocols which have been validated in-house for locus-specific KIR genotyping. The PCR and SSO probe methcdology has been used successfully in the Trachtenberg Laboratory for more than ten years to type many thousands of samples at different immunogenetic loci, including the Human Leukocyte Antigen (HLA)class1 and 11 genes, and more recently the KIR gene complex. Concomitantly, the KIR Genotyping Core Laboratory will finish validation of a novel, higher-throughput single nucleotide polymorphism (SNP)-based method for genotyping the KIR loci using matrix-assisted laser desportion/ionization time-of-flight (MALD1-TOF) mass spectrometry. The accuracy, efficiency and cost-effectiveness of each typing method will then be examined to deternine which method will be used for the bulk of the genotyping in subsequent grant years. The KIR Genotyping Core Laboratory will be responsible for high-throughputKIR genotyping of 7,2<)0 transplant samples (3,600 donor-recipient pairs) in a time-frame necessary to serve the needs of ;hree projects in the program, including Program Projects directed by Drs. Parham, Miller and Weisdorf. As an added level of quality assurance of typing data, atleast 15% of samples will be typed in duplicateby two laboratories (Trachtenberg and Parham), and any discrepancies will be resolved. No other Program laboratory is as sufficiently prepared to provide the rapid KIR genotyping and quality assurance measures necessaryto adequately serve the typing needs of these projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA111412-03
Application #
7550553
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-08-01
Budget End
2008-07-31
Support Year
3
Fiscal Year
2007
Total Cost
$273,757
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Grzywacz, Bartosz; Moench, Laura; McKenna Jr, David et al. (2018) Natural Killer Cell Homing and Persistence in the Bone Marrow After Adoptive Immunotherapy Correlates With Better Leukemia Control. J Immunother :
Sarhan, Dhifaf; Hippen, Keli L; Lemire, Amanda et al. (2018) Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37. Cancer Immunol Res 6:766-775
Williams, Robin L; Cooley, Sarah; Bachanova, Veronika et al. (2018) Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells. Biol Blood Marrow Transplant 24:618-622
Don Yun, Hyun; Felices, Martin; Vallera, Daniel A et al. (2018) Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells. Blood Adv 2:1580-1584
Cooley, Sarah; Parham, Peter; Miller, Jeffrey S (2018) Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation. Blood 131:1053-1062
Williams, Shelly M; Sumstad, Darin; Kadidlo, Diane et al. (2018) Clinical-scale production of cGMP compliant CD3/CD19 cell-depleted NK cells in the evolution of NK cell immunotherapy at a single institution. Transfusion 58:1458-1467
Romee, Rizwan; Cooley, Sarah; Berrien-Elliott, Melissa M et al. (2018) First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood 131:2515-2527
Oh, Felix; Todhunter, Deborah; Taras, Elizabeth et al. (2018) Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin. Clin Pharmacol 10:113-121
Rashidi, Armin; Ebadi, Maryam; Said, Bassil et al. (2018) Absence of early HHV-6 reactivation after cord blood allograft predicts powerful graft-versus-tumor effect. Am J Hematol :
Bachanova, Veronika; Sarhan, Dhifaf; DeFor, Todd E et al. (2018) Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. Cancer Immunol Immunother 67:483-494

Showing the most recent 10 out of 108 publications